Physician profile
Patrick Wayne Blackburn
NPI 1972999266
$6,979.76
in general payments reported to CMS, 2019-2025
39 companies · $2,215 in 2025
The $2,215 reported for 2025 was more than what 79% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $235 · 2021: $600 · 2022: $2,020 · 2023: $507 · 2024: $1,252 · 2025: $2,215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,506 · Consulting Fee: $1,375 · Education: $75.00 · Entertainment: $17.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,505.90 |
| Consulting Fee | $1,375.00 |
| Education | $75.00 |
| Entertainment | $17.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Winter & Ibe Gmbh | $1,375.00 | 2025 | Endoeye Flex Deflectable Videoscope |
| Intuitive Surgical, INC. | $1,080.22 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $897.90 | 2019-2025 | Lynparza, Enhertu, Imfinzi |
| Medical Device Business Services, INC. | $602.02 | 2022 | |
| Glaxosmithkline, LLC. | $588.05 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Eisai INC. | $285.34 | 2021-2023 | |
| Ethicon US, LLC | $219.65 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $204.85 | 2023-2025 | Keytruda, Welireg, Keytruda Qlex |
| Incyte Corporation | $159.06 | 2024-2025 | Monjuvi, Jakafi, Pemazyre |
| Seagen INC. | $151.70 | 2022 | |
| Novartis Pharmaceuticals Corporation | $134.36 | 2024-2025 | |
| Genentech USA, INC. | $130.24 | 2023-2025 | Phesgo, Perjeta, Polivy |
| Daiichi Sankyo INC. | $103.35 | 2024-2025 | Datroway, Enhertu |
| Deciphera Pharmaceuticals INC. | $98.98 | 2023-2025 | Qinlock, Romvimza |
| Genmab U.S., INC. | $90.10 | 2024 | Epkinly, Tivdak |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $84.86 | 2023-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Regeneron Healthcare Solutions, INC. | $68.77 | 2024 | Libtayo |
| Blueprint Medicines Corporation | $64.78 | 2024 | Ayvakit |
| Exelixis INC. | $56.01 | 2025 | Cabometyx |
| Caris Mpi, INC. | $48.37 | 2025 | Mi Cancer Seek |
| Progenics Pharmaceuticals, INC. | $46.79 | 2024-2025 | |
| Legend Biotech USA INC. | $44.42 | 2025 | Carvykti |
| Alexion Pharmaceuticals, INC. | $43.59 | 2024 | Ultomiris |
| Adc Therapeutics America, INC. | $42.64 | 2024 | |
| Rigel Pharmaceuticals, INC. | $32.33 | 2024 | Rezlidhia, Tavalisse |
| Janssen Biotech, INC. | $31.92 | 2024 | Akeega, Erleada, Balversa |
| Karyopharm Therapeutics INC. | $30.20 | 2023-2025 | Xpovio |
| Emd Serono, INC. | $28.28 | 2023 | Bavencio |
| Clovis Oncology, INC. | $26.86 | 2019 | |
| Lilly USA, LLC | $26.74 | 2024 | Verzenio, Jaypirca, Retevmo |
| Abbvie INC. | $26.12 | 2025 | |
| Astellas Pharma US INC | $23.24 | 2024 | Vyloy |
| Beone Medicines USA, INC. | $20.61 | 2025 | Brukinsa |
| Hologic Sales and Service, LLC | $20.44 | 2024 | Myosure Tissue Removal Device |
| Jazz Pharmaceuticals INC. | $20.30 | 2024 | |
| Pfizer INC. | $18.49 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $18.18 | 2024 | Onivyde |
| Baxter Healthcare | $17.72 | 2023 | |
| Provepharm INC. | $17.28 | 2023 | Bludigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Blackburn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.